Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial

EP: 1.Current Standards of Care and Shifting Strategies in NMIBC

EP: 2.NMIBC Treatment Decisions in the Age of BCG Shortages

EP: 3.Expert Discussion on BCG-Unresponsive NMIBC

EP: 4.Bladder-Sparing Breakthroughs: Novel FDA-Approved Treatment Options for NMIBC

EP: 5.Weighing the Risks and Benefits of Bladder-Sparing Agents vs Cystectomy

EP: 6.What’s Next for NMIBC: The Immunotherapy and Gene Therapy Pipeline

EP: 7.Topline Data From the BOND-003 Trial in NMIBC

EP: 8.Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial

Now Viewing

EP: 9.Diving Deeper: Discussing Results From Cohort C in the BOND-003 Trial

EP: 10.Ongoing Investigations: Expanding the Role of Cretostimogene in NMIBC Care

EP: 11.In the Pipeline: Novel Treatment Delivery Methods for NMIBC

EP: 12.Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?

EP: 13.Optimizing NMIBC Treatment Through Sequencing and Patient Preference

EP: 14.The Growing Call for Combination Therapy in NMIBC Treatment

The final results of the BOND-3 trial, recently presented at major urology conferences, have reinforced the promise of intravesical cretostimogene as a treatment for patients with BCG-unresponsive CIS with or without papillary disease. In this study, patients received an initial induction course of weekly installations of cretostimogene, and those with persistent high-grade disease could undergo a second induction phase before moving to a maintenance protocol similar to what has been seen in prior BCG trials. With 112 participants, BOND-3 became the largest trial conducted in this specific patient population to date.

The efficacy data are particularly compelling. The trial demonstrated a complete response rate of approximately 46% at 12 months, with an overall response rate at any time nearing 76%. Among responders, the durability was impressive, with a median duration of response exceeding 28 months. This suggests that for those who benefit from the treatment, the response is not only meaningful but also long-lasting. Furthermore, with a 97% freedom from progression to muscle-invasive bladder cancer and a 90% cystectomy-free survival rate at 1 year, the therapy supports bladder preservation in a majority of patients—an outcome that is often highly prioritized in this setting.

Safety and tolerability were also key strengths of the BOND-3 study. The vast majority of adverse events were mild (grade 1/2), with no grade 3 or higher treatment-related events reported. Additionally, these adverse effects were short-lived, with a median duration of just one day, and no patients had to discontinue therapy due to adverse events. These findings reinforce cretostimogene’s potential as a safe, durable, and effective immunotherapeutic option for managing BCG-unresponsive disease, highlighting the value of ongoing innovation in intravesical therapies.